

Supplementary Table 1. Comparison between Lamivudine and Entecavir according to the Subgroup

Subgroup	Patients no.	Survival rate, % (entecavir vs lamivudine)		p-value
		1-Year	5-Years	
All	249 vs 202	65.4 vs 59.4	46.1 vs 33.1	0.002
mUICC stage I/II	122 vs 94	83.6 vs 81.9	70.4 vs 54.2	0.007
mUICC stage III/IV	127 vs 108	48.8 vs 37.9	22.8 vs 14.8	0.054
HBV DNA <20,000 IU/mL	45 vs 49	62.2 vs 48.0	48.8 vs 40.0	0.23
HBV DNA ≥20,000 IU/mL	204 vs 153	66.1 vs 63.1	45.5 vs 30.9	0.004
Child-Pugh class A	200 vs 145	73.0 vs 51.5	64.8 vs 38.6	0.004
Child-Pugh class B/C	49 vs 57	34.6 vs 42.1	24.4 vs 19.3	0.99
Previous decompensation (no)	174 vs 144	79.8 vs 72.2	59.2 vs 40.2	<0.001
Previous decompensation (yes)	75 vs 58	32.0 vs 24.1	16.0 vs 15.5	0.559
CVR within year	94 vs 33	90.5 vs 84.8	72.6 vs 39.4	<0.001
CVR during follow-up	139 vs 92	92.8 vs 90.2	79.9 vs 60.9	<0.001
No CVR during follow-up	53 vs 46	49.1 vs 60.9	5.7 vs 17.4	0.033
No evaluation of CVR	57 vs 64	14.0 vs 10.9	1.8 vs 4.7	0.95
Curative therapy	110 vs 67	94.5 vs 92.5	83.6 vs 65.6	0.004
Palliative therapy	139 vs 135	42.4 vs 42.9	16.5 vs 17.0	0.73
Mortality <a year	86 vs 84	4.0 vs 3.8*	-	0.95
Mortality ≥a year	163 vs 118	-	70.5 vs 56.7	0.004

mUICC, modified Union for International Cancer Control; HBV, hepatitis B virus; CVR, complete virological response.

*Median survival duration (mo); all deaths occurred within 1 year.